Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
Tanda ET, d'Amato AL, Rossi G, Croce E, Boutros A, Cecchi F, Spagnolo F, Queirolo P. Tanda ET, et al. Among authors: boutros a. Front Oncol. 2021 Sep 23;11:739006. doi: 10.3389/fonc.2021.739006. eCollection 2021. Front Oncol. 2021. PMID: 34631574 Free PMC article. Review.
The adjuvant treatment revolution for high-risk melanoma patients.
Spagnolo F, Boutros A, Tanda E, Queirolo P. Spagnolo F, et al. Among authors: boutros a. Semin Cancer Biol. 2019 Dec;59:283-289. doi: 10.1016/j.semcancer.2019.08.024. Epub 2019 Aug 21. Semin Cancer Biol. 2019. PMID: 31445219 Review.
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization.
Mastracci L, Fontana V, Queirolo P, Carosio R, Grillo F, Morabito A, Banelli B, Tanda E, Boutros A, Dozin B, Gualco M, Salvi S, Romani M, Spagnolo F, Poggi A, Pistillo MP. Mastracci L, et al. Among authors: boutros a. Cancer Immunol Immunother. 2020 Apr;69(4):653-662. doi: 10.1007/s00262-020-02494-y. Epub 2020 Feb 5. Cancer Immunol Immunother. 2020. PMID: 32025849 Free PMC article.
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F, Croce E, Boutros A, Tanda E, Cecchi F, Mascherini M, Solari N, Cafiero F, Queirolo P. Spagnolo F, et al. Among authors: boutros a. Expert Rev Anticancer Ther. 2020 May;20(5):403-413. doi: 10.1080/14737140.2020.1760847. Epub 2020 May 3. Expert Rev Anticancer Ther. 2020. PMID: 32326767 Review.
Current State of Target Treatment in BRAF Mutated Melanoma.
Tanda ET, Vanni I, Boutros A, Andreotti V, Bruno W, Ghiorzo P, Spagnolo F. Tanda ET, et al. Among authors: boutros a. Front Mol Biosci. 2020 Jul 14;7:154. doi: 10.3389/fmolb.2020.00154. eCollection 2020. Front Mol Biosci. 2020. PMID: 32760738 Free PMC article. Review.
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.
Vanni I, Tanda ET, Dalmasso B, Pastorino L, Andreotti V, Bruno W, Boutros A, Spagnolo F, Ghiorzo P. Vanni I, et al. Among authors: boutros a. Front Mol Biosci. 2020 Jul 24;7:172. doi: 10.3389/fmolb.2020.00172. eCollection 2020. Front Mol Biosci. 2020. PMID: 32850962 Free PMC article. Review.
95 results